

CORPORATE INFORMATION

BOARD OF DIRECTORS

John C. Martin, PhD
Chairman, Gilead Sciences

Jacqueline K. Barton, PhD
Professor of Chemistry, California
Institute of Technology

John F. Cogan, PhD
Senior Fellow, Hoover Institution,
Stanford University
Lead Independent Director,
Gilead Sciences

Kelly A. Kramer
Executive Vice President and Chief
Financial Officer, Cisco Systems

Kevin E. Lofton
Chief Executive Officer,
Catholic Health Initiatives

John F. Milligan, PhD
President and Chief Executive Officer,
Gilead Sciences

Nicholas G. Moore
Retired Global Chairman,
PricewaterhouseCoopers

Richard J. Whitley, MD
Distinguished Professor,
Loeb Scholar Chair in Pediatrics,
Professor of Pediatrics, Microbiology,
Medicine, and Neurosurgery,
University of Alabama at Birmingham

Gayle E. Wilson
Retired California's First Lady

Per Wold-Olsen
Retired President, Human Health
Intercontinental Division, Merck & Co.

DIRECTOR EMERITUS, BOARD OF DIRECTORS

George P. Shultz, PhD
Distinguished Fellow, Hoover Institution,
Stanford University

SENIOR MANAGEMENT TEAM

John F. Milligan, PhD
President and Chief Executive Officer

Gregg H. Alton
Executive Vice President,
Corporate and Medical Affairs
Interim Head,
International Commercial Operations

Norbert W.
Bischofberger, PhD
Executive Vice President, Research and
Development and Chief Scientific Officer

Andrew Cheng, MD, PhD
Executive Vice President, Clinical
Research and Development Operations

William A. Lee, PhD
Executive Vice President, Research

John McHutchison, MD
Executive Vice President,
Clinical Research

Brett A. Pletcher
Executive Vice President, General Counsel
and Chief Compliance Officer

Alessandro Riva, MD
Executive Vice President,
Oncology Therapeutics

Martin B. Silverstein, MD
Executive Vice President, Strategy

Robin L. Washington
Executive Vice President and
Chief Financial Officer

Katie L. Watson
Executive Vice President,
Human Resources

Taiyin Yang, PhD
Executive Vice President, Pharmaceutical
Development and Manufacturing

SCIENTIFIC ADVISORY BOARD

Joel R. Huff, PhD (Chairperson)
Retired, Vice President of Medicinal
Chemistry, Merck Research Laboratories

Nezam H. Afdhal, MD
Chief of Hepatology and Director of
the Liver Center, Beth Israel Deaconess
Medical Center, Professor of Medicine,
Harvard Medical School

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine,
Harvard Medical School, Director, LeBow
Institute for Myeloma Therapeutics,
Director, Jerome Lipper Multiple Myeloma
Center, Dana-Farber Cancer Institute

Paul Berg, PhD
Robert K. and Vivian K. Cahill Professor,
Emeritus, Stanford University School
of Medicine

Brian J. Druker, MD
Director, Knight Cancer Institute,
Associate Dean for Oncology, School
of Medicine, JELD-WEN Chair of
Leukemia Research, Oregon Health
& Science University, Investigator,
Howard Hughes Medical Institute

Mark C. Genovese, MD
James W. Raitt Endowed Professor of
Medicine, Co-Division Chief Division
of Immunology and Rheumatology,
Stanford University School of Medicine

Robert (Bob) A. Harrington, MD
Arthur L. Bloomfield Professor of
Medicine, Chair, Department of Medicine,
Stanford University School of Medicine

Malcolm MacCoss, PhD, FRSC
Founder and Member, Bohicket Pharma
Consulting LLC, Visiting Professor of
Chemistry for Medicine, University of
Oxford, UK

John W. Mellors, MD
Professor of Medicine, Chief, Division
of Infectious Diseases, University of
Pittsburgh School of Medicine

Robert T. Schooley, MD
Professor of Medicine, Division of Infec-
tious Diseases, Vice Chair of Department
of Medicine, Senior Director of Interna-
tional Initiatives, University of California,
San Diego

CORPORATE SECRETARY

Brett A. Pletcher
General Counsel/Corporate Secretary

INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

Ernst & Young LLP
Redwood City, California

CORPORATE HEADQUARTERS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
(800) 445-3235 or (650) 574-3000
www.gilead.com

STOCKHOLDER INQUIRIES

Inquiries from our stockholders and
potential investors regarding our
company are always welcome and will

receive a prompt response. Please
direct your requests for information to
Investor Relations.

INVESTOR RELATIONS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
(800) 445-3235 or (650) 574-3000

Information regarding Gilead also is
available at www.gilead.com

STOCK LISTING

Gilead common stock is traded on the
Nasdaq Global Select Stock Market,
under the symbol GILD.

ANNUAL MEETING

The annual meeting of stockholders
will be held at 10:00 a.m. on
Wednesday, May 9, 2018, at the Westin
San Francisco Airport Hotel.

TRANSFER AGENT AND REGISTRAR

Communications concerning stock
transfer requirements, lost certificates
and changes of address should be
directed to the Transfer Agent:

Computershare
P.O. BOX 30170
College Station, TX 77842-3170
(800) 710-0940
www.computershare.com/investor

EQUAL OPPORTUNITY EMPLOYER

Gilead Sciences is proud to be an equal
opportunity employer and extends
employment to men and women from
culturally diverse backgrounds. Our
environment respects individual differ-
ences and recognizes each employee
as an integral member of our company.
Our workforce reflects these values and
celebrates the individuals who make up
our growing team.